secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2025-10-15T23:59:59+00:00
Accession:  0001493152-25-018093
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity regains Nasdaq compliance; stock continues trading on Capital Market
--------------------------------------------------------------------------------

- Received Nasdaq letter Oct 14 confirming compliance with minimum bid price ($1.00) and stockholders' equity ($2.5M) rules.
- Subject to one-year Mandatory Panel Monitor; if equity rule breached, no additional time to regain compliance but hearing available.
- Common stock (BIAF) and warrants (BIAFW) continue trading on Nasdaq Capital Market.
- CEO Maria Zannes: regaining compliance allows focus on CyPath Lung test and building shareholder value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315225018093/0001493152-25-018093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315225018093/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-018093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer